Sophia Apple

Sophia K. Apple, MD

Associate Professor, Department of Pathology and Laboratory Medicine
Director of Breast Pathology
Director of Cytology Fellowship
Member, JCCC Community


English, Korean


Breast Pathology, Pathology

Institutional Affiliation

Ronald Reagan UCLA Medical Center
UCLA Medical Center, Santa Monica



Cytopathology, UCLA School of Medicine, 1997 - 1998


MD, Wright State University School of Medicine, 1992


Pathology, UCLA School of Medicine, 1992 - 1997

Board Certifications

Cytopathology, American Board of Pathology, 1998
Anatomic Pathology and Clinical Pathology, American Board of Pathology, 1997

Contact Information

Clinical Interests

Breast Pathology

Scientific Interests

Dr. Sophia Apple's research focuses on factors associated with the development of breast cancer, features associated with breast cancer biomarkers and triple negative breast cancer.

Highlighted Publications

Vergara-Lluri ME, Moatamed NA, Hong E, Apple SK. High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines. Mod Pathol. 2012 Oct;25(10):1326-32. doi: 10.1038/modpathol.2012.93. Epub 2012 Jun 15.

Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY, Apple SK. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 2011 Nov;136(5):754-61. doi: 10.1309/AJCP99WZGBPKCXOQ.

Apple S, Pucci R, Lowe AC, Shintaku I, Shapourifar-Tehrani S, Moatamed N. The effect of delay in fixation, different fixatives, and duration of fixation in estrogen and progesterone receptor results in breast carcinoma. Am J Clin Pathol. 2011 Apr;135(4):592-8. doi: 10.1309/AJCPB1RIT5YXMRIS.

Konecny GE, Pauletti G, Untch M, Wang HJ, Mobus V, Kuhn W, Thomssen C, Harbeck N, Wang L, Apple S, Janicke F, Slamon DJ. Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancer. Breast Cancer Res Treat. 2010 Apr;120(2):481-9. doi: 10.1007/s10549-010-0744-z. Epub 2010 Feb 4.

Apple SK, Lowe AC, Rao PN, Shintaku IP, Moatamed NA. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol. 2009 Sep;22(9):1151-9. doi: 10.1038/modpathol.2009.82. Epub 2009 May 29.